Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart M Sprague

Showing results (61-70 of 116) with videos related to

Pageof 12
Sort By:
Kidney360|October 23, 2023
Managing Phosphate Burden in Patients Receiving Dialysis: Beyond Phosphate Binders and DietKamyar Kalantar-Zadeh, Derek Forfang, George Bakris, et al.
Investigative Radiology|July 21, 2015
Renal Blood Oxygenation Level-Dependent Magnetic Resonance Imaging: A Sensitive and Objective AnalysisJon M Thacker, Lu-Ping Li, Wei Li, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|April 16, 2018
Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patientsStuart M Sprague, Markus Ketteler, Adrian C Covic, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 8, 2020
Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammationJürgen Floege, Felix Funk, Markus Ketteler, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 26, 2016
Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxideAdrian C Covic, Jürgen Floege, Markus Ketteler, et al.
Nephron|June 26, 2020
Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 StudyAdrian C Covic, Stuart M Sprague, Anjay Rastogi, et al.
Current Medical Research and Opinion|July 23, 2024
Effectiveness of tenapanor for treating hyperphosphatemia in patients receiving dialysis: a plain language summary of the OPTIMIZE studyStuart M Sprague, Susan Edelstein, David M Spiegel, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 9, 2004
Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settingsDeborah G Dobrez, Angelo Mathes, Michael Amdahl, et al.
American Journal of Nephrology|July 20, 2016
Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis PatientsStuart M Sprague, Adrian C Covic, Jürgen Floege, et al.
Transplantation|October 27, 2004
Calcium and calcitriol prophylaxis attenuates posttransplant bone lossMichelle A Josephson, L Philip Schumm, May Y Chiu, et al.
Pageof 12

Showing results (61-70 of 116) with videos related to

Sort By:
Pageof 12
Kidney360|October 23, 2023
Managing Phosphate Burden in Patients Receiving Dialysis: Beyond Phosphate Binders and DietKamyar Kalantar-Zadeh, Derek Forfang, George Bakris, et al.
Investigative Radiology|July 21, 2015
Renal Blood Oxygenation Level-Dependent Magnetic Resonance Imaging: A Sensitive and Objective AnalysisJon M Thacker, Lu-Ping Li, Wei Li, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|April 16, 2018
Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patientsStuart M Sprague, Markus Ketteler, Adrian C Covic, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 8, 2020
Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammationJürgen Floege, Felix Funk, Markus Ketteler, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 26, 2016
Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxideAdrian C Covic, Jürgen Floege, Markus Ketteler, et al.
Nephron|June 26, 2020
Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 StudyAdrian C Covic, Stuart M Sprague, Anjay Rastogi, et al.
Current Medical Research and Opinion|July 23, 2024
Effectiveness of tenapanor for treating hyperphosphatemia in patients receiving dialysis: a plain language summary of the OPTIMIZE studyStuart M Sprague, Susan Edelstein, David M Spiegel, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 9, 2004
Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settingsDeborah G Dobrez, Angelo Mathes, Michael Amdahl, et al.
American Journal of Nephrology|July 20, 2016
Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis PatientsStuart M Sprague, Adrian C Covic, Jürgen Floege, et al.
Transplantation|October 27, 2004
Calcium and calcitriol prophylaxis attenuates posttransplant bone lossMichelle A Josephson, L Philip Schumm, May Y Chiu, et al.
Pageof 12